Invention Grant
- Patent Title: Super enhancer for driving pluripotency network and stemness circuitry
-
Application No.: US17003799Application Date: 2020-08-26
-
Publication No.: US11866734B2Publication Date: 2024-01-09
- Inventor: Shih-Hwa Chiou , Ping-Hsing Tsai , Yueh Chien
- Applicant: Taipei Veterans General Hospital
- Applicant Address: TW Taipei
- Assignee: TAIPEI VETERANS GENERAL HOSPITAL
- Current Assignee: TAIPEI VETERANS GENERAL HOSPITAL
- Current Assignee Address: TW Taipei
- Agency: Birch, Stewart, Kolasch & Birch, LLP
- Main IPC: C12N5/074
- IPC: C12N5/074 ; C12N15/86

Abstract:
The preset invention relates to a novel super-enhancer-bound Ash2l/OSN complex that can drive enhance activation, govern pluripotency network and sternness circuitry, and a reprogramming system or method through the regulation of this super-enhancer, Ash2l, to modulate pluripotency and cell fates. Ash2l directly binds to super-enhancers of several stemness genes to regulate pluripotency and self-renewal in pluripotent stem cells. Ash2l recruits Oct4/Sox2/Nanog (OSN) to form Ash2l/OSN complex at the super-enhancers of Jarid2, Nanog, Sox2, and Oct4, and further drives enhancer activation, upregulation of stemness genes, and maintains the pluripotent circuitry. Ash2l knockdown abrogates the OSN recruitment to all super-enhancers and further hinders the enhancer activation. In addition, CRISPRi/dCas9-mediated blocking of Ash2l-binding motifs at these super-enhancers also prevents OSN recruitment and enhancer activation, validating that Ash2l directly binds to super-enhancers and initiates the pluripotency network. Transfection of Ash2l with W118A mutation to disrupt Ash2l-Oct4 interaction fails to rescue Ash2l-driven enhancer activation and pluripotent gene upregulation in Ash2l-depleted pluripotent stem cells.
Public/Granted literature
- US20210102174A1 SUPER ENHANCER FOR DRIVING PLURIPOTENCY NETWORK AND STEMNESS CIRCUITRY Public/Granted day:2021-04-08
Information query